Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.

被引：0
|
作者：
Gattermann, Norbert [1 ]
Sanz, Guillermo F. [2 ]
Giagounidis, Aristoteles [3 ]
Seymour, John F. [4 ]
Fenaux, Pierre [5 ]
Santini, Valeria [6 ]
Mufti, Ghulam J. [7 ]
Muus, Petra [8 ]
Ramos, Fernando [9 ,10 ]
Lucy, Lela M. [11 ]
Beach, C. L. [11 ]
Silverman, Lewis R. [12 ]
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol, Dusseldorf, Germany
[2] Hosp Univ La Fe, Dept Hematol, Valencia, Spain
[3] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
[6] UF Ematol AOU Careggi, Florence, Italy
[7] Kings Coll Hosp London, London, England
[8] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands
[9] Hosp Leon, Leon, Spain
[10] IBIOMED, Leon, Spain
[11] Celgene Corp, Overland Pk, KS USA
[12] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1643 / 1644
页数：2
相关论文
共 50 条
  • [41] EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Fenaux, P.
    Gattermann, N.
    Seymour, J.
    Hellstrom-Lindberg, E.
    Mufti, G. J.
    Duehrsen, U.
    Gore, S.
    Ramos, F.
    Beyne-Rauzy, O.
    Dombret, H.
    List, A.
    McKenzie, D.
    Backstrom, J.
    Allen, A.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 90 - 90
  • [42] Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS)
    Yang, Wei
    Gao, Sujun
    Yan, Xiaojing
    Guo, Rong
    Han, Lijie
    Li, Fei
    Wang, Yafei
    Li, Junmin
    Chang, Chunkang
    Yang, Haiping
    Hu, Ronghua
    Tong, Hongyan
    Zhao, Xingli
    Li, Qiubai
    Zhang, Jingdong
    Du, Xin
    Dong, Zheng
    Lu, Qiying
    Tian, Wenzhi
    Xiao, Zhi-Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Barkalifa, Ronit
    Vigil, Carlos E.
    Prebet, Thomas
    Komrokji, Rami
    Giagounidis, Aristoteles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S364 - S364
  • [44] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
    Zhou, Xiaofei
    Mould, Diane R.
    Zhao, Dan
    Sekeres, Mikkael A.
    Ades, Lionel
    Swords, Ronan T.
    Handa, Hiroshi
    Fram, Robert J.
    Faller, Douglas V.
    Tsukurov, Olga
    Gupta, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study
    Arnan, Montserrat
    Coll, Rosa
    Tormo, Mar
    Maria Bastida, Jose
    Calbacho, Maria
    Bernal, Teresa
    Ramos, Fernando
    Somolinos, Nieves
    Pedro, Carmen
    Albors, Manuel
    Marchante, Inmaculada
    Brunet, Salut
    Rafel, Montse
    Valcarcel, David
    BLOOD, 2015, 126 (23)
  • [46] A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Barkalifa, Ronit
    Vigil, Carlos Enrique
    Prebet, Thomas
    Komrokji, Rami S.
    Giagounidis, Aristoteles
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    A G Dinmohamed
    Y van Norden
    O Visser
    E F M Posthuma
    P C Huijgens
    P Sonneveld
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2015, 29 : 2449 - 2451
  • [48] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry
    Dinmohamed, A. G.
    van Norden, Y.
    Visser, O.
    Posthuma, E. F. M.
    Huijgens, P. C.
    Sonneveld, P.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2015, 29 (12) : 2449 - 2451
  • [49] Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial
    Garcia-Manero, Guillermo
    Yee, Karen W. L.
    Hernandez, Francisca
    Della Porta, Matteo Giovanni
    Paolini, Stefania
    Ahn, Seo-Yeon
    Santini, Valeria
    Fenaux, Pierre
    Suzuki, Takahiro
    Sekeres, Mikkael A.
    He, Jun
    Li, Jerry
    Barkalifa, Ronit
    Vigil, Carlos E.
    Prebet, Thomas
    de Menezes, Daniel Lopes
    Burnett, Joseph
    Komrokji, Rami S.
    Giagounidis, Aristoteles
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
    Hasegawa, Ken
    Wei, Andrew H.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Rajakumaraswamy, Nishanthan
    Iqbal, Shahed
    Chan, Rebecca J.
    Hu, Hao
    Tse, Preston
    Yan, Jiajun
    Zoratti, Michael J.
    Xie, Feng
    Sallman, David Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345